NVS remibrutinib shows favorable Phase III RMS results
Newsdesk says NVS remibrutinib reduced relapse rates and had a favorable safety profile in Phase III RMS trials.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.